Brief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
13/10/2026 13:15
BRIEF-Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer Oct 13 (Reuters) - Prelude Therapeutics Incorporated PRLD.O:
PRELUDE ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH LILLY TO EVALUATE KAT6A SELECTIVE DEGRADER PRT13722 IN COMBINATION WITH VERZENIO® AND INLURIYO® IN PATIENTS WITH HR+/HER2- BREAST CANCER
PRELUDE THERAPEUTICS INCORPORATED - AGREEMENT SUPPORTS EVALUATION OF PRT13722 WITH ABEMACICLIB AND IMLUNESTRANT IN PHASE 1 TRIAL
PRELUDE THERAPEUTICS INCORPORATED - EXPECTS TO BEGIN ENROLLMENT FOR PHASE 1 TRIAL IN Q4 2026
PRELUDE THERAPEUTICS INCORPORATED - MAINTAINS FULL GLOBAL DEVELOPMENT AND COMMERCIAL RIGHTS TO PRT13722
Source text: ID:nGNX97sbVy
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview